IBT Portfolio Manager Says KalVista Deal Signals Biotech 2.0 Growth

Why It Matters

The KalVista deal illustrates how pharma’s patent cliff is accelerating acquisitions of independent biotech innovators, creating significant upside for investors positioned in the emerging Biotech 2.0 space.

Key Takeaways

• IBT recorded fifth acquisition in 2026, boosting portfolio returns.
• Large pharma face $100B+ patent expiries, driving biotech demand.
• Biotech 2.0 firms launch independently, reducing reliance on pharma partners.
• KalVista’s oral EKTERLY fetched 36% premium, exemplifying value upside.
• IBT plans rapid cash redeployment into similar high‑premium targets.

Summary

International Biotechnology Trust’s portfolio manager Ailsa Craig explained that the KalVista Pharmaceuticals acquisition marks the fund’s fifth deal in 2026, underscoring a surge in biotech‑focused M&A. The transaction, which lifted KalVista’s share price from $5 to $27, delivered a 36% premium to shareholders and contributed to 15% of the trust’s net asset value being acquired this year.

Craig highlighted the macro backdrop: large‑cap pharma companies are cash‑rich but face hundreds of billions of dollars in upcoming patent expiries, forcing them to seek external pipelines. Over the past decade, internal R&D has underperformed, and last year 70% of new drug approvals came from biotech firms. This supply‑demand mismatch fuels the “Biotech 2.0” wave—independent companies that have clinically de‑risked assets and can launch products without pharma support.

KalVista exemplifies this model with its oral tablet EKTERLY, which replaces injectable therapy and has already demonstrated strong market uptake. The fund’s acquisition premium averages 50% this year, slightly below last year’s 66% but still indicative of robust valuation for clinically validated assets. Craig noted that IBT exits positions as soon as deals are announced, redeploying capital into similar high‑potential opportunities.

The broader implication is that biotech companies capable of independent commercialization are becoming prime targets for cash‑rich pharma, offering investors outsized upside and reinforcing IBT’s strategy of rapid cash recycling into next‑generation innovators.

Original Description

International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig tells Proactive's Stephen Gunnion that M&A activity in biotech is running hot, with the proposed KalVista Pharmaceuticals acquisition by Chiesi Farmaceutici the latest in a string of deals — and 15% of IBT's portfolio has now been acquired year-to-date at an average premium of 50%.

Craig explains the structural driver: big pharma is cash-rich but facing hundreds of billions in revenues lost to patent expiries, forcing them to acquire innovation. With biotech firms accounting for 70% of new drug approvals last year, the sector is firmly in the crosshairs.

KalVista is held up as a textbook example of what Craig calls "Biotech 2.0" — clinically de-risked companies addressing real unmet needs. Its oral HAE treatment replaced injectable therapies, and Craig puts it simply: when patients feel an attack coming on, they now just take a tablet.

IBT recycles proceeds from exits straight back into new opportunities, keeping the portfolio actively positioned to benefit from continued dealflow.

For more insights like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss future updates.

#Biotech #Pharma #MergersAndAcquisitions #BiotechInvesting #HealthcareStocks #KalVista #DrugDevelopment #InvestingInsights #BiotechNews #PharmaIndustry #StockMarket #HealthcareInnovation